Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rademikibart - Suzhou Connect Biopharmaceuticals

Next Previous
Drug Profile

Rademikibart - Suzhou Connect Biopharmaceuticals

Alternative Names: CBP 201

Latest Information Update: 22 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Suzhou Connect Biopharmaceuticals
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Interleukin 4 receptor alpha subunit antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Asthma; Atopic dermatitis

Highest Development Phases

  • Phase III Asthma; Atopic dermatitis
  • Phase II Chronic obstructive pulmonary disease; Rhinosinusitis
  • No development reported Nasal polyps

Most Recent Events

  • 13 May 2025 Phase-II clinical trials in Asthma (In adolescents, In adults, In the elderly, Adjunctive treatment) in USA (SC) (NCT06940141)
  • 07 May 2025 Suzhou Connect Biopharmaceuticals plans a phase II Seabreeze STAT COPD trial for Chronic obstructive pulmonary disease (Adjunctive treatment) (SC), in May 2025 (NCT06940154)
  • 06 May 2025 Suzhou Connect Biopharmaceuticals plans a phase II Seabreeze STAT Asthma trial for Asthma (Adjunctive treatment, In adolescents, In adults, In the elderly) (SC), in May 2025 (NCT06940141)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top